In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary

  

allogeneic renal cell carcinoma vaccine MGN1601 
A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonym:IL-7/GM-CSF/CD80/CD154-encoding synthetic dSLIM-30L1 allogeneic renal cell carcinoma vaccine MGN1601
Code name:MGN1601